3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Ovarian Neoplasms
39
Breast Neoplasms
24
Neoplasms
12
Prostatic Neoplasms
11
Triple Negative Breast Neoplasms
9
Parkinson Disease 4, Autosomal Dominant Lewy Body
7
Pancreatic Neoplasms
7
Neoplasm Metastasis
7
Carcinoma, Ovarian Epithelial
6
Stomach Neoplasms
5
Metastatic Castration-resistant Prostate Cancer
5
Fanconi Anemia, Complementation Group D1
5
Small Cell Lung Carcinoma
4
Carcinoma, Non-Small-Cell Lung
4
Advanced Solid Tumors
4
Solid Tumors
3
Fallopian Tube Neoplasms
3
Endometrial Neoplasms
3
Prostatic Neoplasms, Castration-Resistant
2
Colorectal Neoplasms
2
Carcinoma
2
Advanced Solid Tumours
2
Advanced Solid Tumor
2
Urogenital Neoplasms
1
Urinary Bladder Neoplasms
1
Triple Negative Metastatic Breast Cancer
1
Squamous Cell Carcinoma of Head and Neck
1
Prostatic Diseases
1
Platinum-sensitive Ovarian Cancer
1
Platinum Refractory Extensive-Stage Small Cell Lung Carcinoma
1
Interventions
Carboplatin
13
Paclitaxel
8
Bevacizumab
7
Gemcitabine
4
130-nm albumin-bound paclitaxel
4
liposomal doxorubicin
3
relacorilant
2
pembrolizumab
2
nintedanib
2
epothilone B
2
Drug Therapy
2
Albumin-Bound Paclitaxel
2
volociximab
1
tremelimumab
1
phenoxodiol
1
oregovomab
1
olaparib
1
lanreotide
1
farletuzumab
1
enzastaurin
1
durvalumab
1
cc-486
1
catumaxomab
1
atezolizumab
1
Trastuzumab
1
Trabectedin
1
Topotecan
1
Saline Solution
1
Oxaliplatin
1
Octreotide
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Peritoneal Neoplasms
×
olaparib
×
Clear all
NCT03740165
2026-05-04
KEYLYNK-001
Merck Sharp & Dohme LLC
Phase 3
Completed
1,367 enrolled
29 charts